Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise in shrinking lung tumors before surgery

NCT ID NCT07452003

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Mar 20, 2026 · Last updated May 14, 2026 · Updated 8 times

Summary

This study tests a new drug called QL1706 (a type of immunotherapy) combined with standard chemotherapy for people with a certain stage of non-small cell lung cancer that can be removed with surgery. About 30 participants will receive the drug combination before surgery to shrink the tumor, then have surgery, and be followed afterward. The main goal is to see how many patients have very little or no cancer left in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER